Document is current
Any future updates will be listed below
-
Authors
Srivastava, Arjun V. https://orcid.org/0000-0002-6169-8209
Nemeroff, Charles B. https://orcid.org/0000-0001-7867-1160
O’Sullivan, Sean J.
- License Information
-
More Information
Article History
Received: 22 March 2025
Revised: 17 November 2025
Accepted: 25 January 2026
First Online: 10 February 2026
Competing interests
: Dr. Arjun Srivastava has no conflicts of interest to declare. Dr. Sean O’Sullivan has no conflicts of interest to declare. Dr. Charles Nemeroff is supported by the National Institutes of Health, the National Institute of Mental Health, and the National Institute of Alcohol Abuse and Alcoholism. Charles Nemeroff is a consultant for ANeuroTech (division Anima BV), Janssen Research and Development, BioXcel Therapeutics, Engrail Therapeutics, Clexio Biosciences LTD, EmbarkNeuro, Galen Mental Health LLC, Goodcap Pharmaceuticals, ITI Inc, LUCY Scientific Discovery, Relmada Therapeutics, Sage Therapeutics, Senseye Inc, Precisement Health, Autobahn Therapeutics Inc, EMA Wellness, Skyland Trails, Denovo Biopharma, Alvogen, Acadia Pharmaceuticals, Inc., and the Brain & Behavior Research Foundation. Charles Nemeroff owns the following patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551, 996 B2). Charles Nemeroff owns stock in Corcept Therapeutics Company, EMA Wellness, Precisement Health, Relmada Therapeutics, Signant Health, Galen Mental Health LLC, and Senseye Inc.
